

GENERAL INFORMATION

AUSPICES

- Azienda Ospedaliero - Universitaria di Parma
- Università di Parma
- SIES - Società Italiana di Ematologia Sperimentale

MEETING VENUE

Sala Congressi
Azienda Ospedaliero-Universitaria
Viale A. Gramsci, 14 - 43126 Parma

CME

An application for Italian CME credits has been made as follows:

- Provider Studio ER Congressi SRL: ID 828-291945
- No. 6 CME credits for Physicians
(disciplines: family practice/general medicine, hematology, internal medicine, nephrology, oncology) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

REGISTRATION

The registration is free. It is possible to register on the website www.ercongressi.it, section *Congressi/2021*.

SCIENTIFIC COORDINATOR

Prof. Nicola Giuliani

Dipartimento di Medicina e Chirurgia
Università di Parma
Azienda Ospedaliero-Universitaria di Parma

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559 - Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it



EVENTO

ParmAIL 2021

Myeloma Research Workshop
from the bedside to the bench

PARMA | 28 SETTEMBRE 2021

Azienda Ospedaliero-Universitaria, Sala Congressi

Responsabile Scientifico: **Nicola Giuliani**

Presidente ParmAIL: **Vittorio Rizzoli**

09.00-09.30 Introduzione all'evento e saluto delle autorità
N. Giuliani, Parma

09.30-09.45 Ruolo dell'AIL
V. Rizzoli, Parma

09.45-10.30 SESSIONE DEDICATA AI PAZIENTI

Chairmen: **M. Luppi, Modena** - **D. Vallisa, Piacenza**

Modelli di assistenza domiciliare nei pazienti con mieloma multiplo

M.T. Petrucci, Roma

L'assistenza domiciliare a Parma

M. Crugnola, Parma

Confronto fra specialisti e pazienti con mieloma multiplo:
quali problematiche?

B. Dalla Palma, Parma

10.30-10.45 Coffee break

10.45-11.15 SESSION I: STANDARD TREATMENT OF MULTIPLE MYELOMA PATIENTS IN THE REAL LIFE

Chairmen: **M. Boccadoro, Torino** - **M. Cavo, Bologna**

How I treat a transplant eligible patient

G. Buda, Pisa

How I treat an elderly and frail patient

A. Larocca, Torino

11.15-11.45 SESSION II: ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA

Debate

Chairperson: **A. Olivieri, Ancona**

YES

L. Prezioso, Parma

NO

B. Dalla Palma, Parma

11.45-12.15 SESSION III: NEW IMMUNO-THERAPEUTIC APPROACHES IN MULTIPLE MYELOMA PATIENTS

Chairmen: **M. Petrini, Pisa** - **G. Semenzato, Padova**

How targeted CD38 and adenosine in multiple myeloma

F. Malavasi, Torino

New monoclonal antibodies

P. Musto, Bari

12.15-12.45 SESSION IV: MYELOMA BONE DISEASE

Chairman and discussant: **N. Giuliani, Parma**

Lecture (online)

The pathophysiology and treatment of myeloma bone disease

G.D. Roodman, Indianapolis

12.45-13.45 Lunch

13.45-15.45 SESSION V: THE BIOLOGY OF MULTIPLE MYELOMA

The plasma cell clone, genomics and myeloma development

Chairmen: **A. Cuneo, Ferrara** - **G. Gaidano, Novara** - **A. Neri, Milano**

The genomic of smoldering myeloma

N. Bolli, Milano

Non-coding RNA profiling in multiple myeloma

L. Agnelli, Milano

The myeloma propagating cells and the side population

C. Terragna, Bologna

Role of Amp1q in multiple myeloma

S. Colla, Houston (Online)

The critical role of the microenvironment

Chairmen: **F. Di Raimondo, Catania** - **M. Massaia, Cuneo**

Endothelial cells in multiple myeloma

R. Ria, Bari

Transcriptome of myeloma bone microenvironment

P. Storti, Parma

Role of ICOS/ICOSL in myeloma microenvironment

U. Dianzani, Novara

Targeting kinases in MM cells to overcome drug resistance

F. Piazza, Padova

15.45-16.15 SESSION VI: TRANSLATIONAL RESEARCH LINES SUPPORTED BY ParmAIL

Chairmen: **N. Giuliani, Parma** - **G. Roti, Parma**

SARS-Cov-2 in patients with MGUS and multiple myeloma

R. Vescovini, Parma

Oncolytic virotherapy

V. Marchica, Parma

16.15 -17.00

Conclusions

N. Giuliani, Parma



EVENTO
ParmAIL
2021

Myeloma Research Workshop
from the bedside to the bench